{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:18:22Z","timestamp":1792113502934,"version":"4.4.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s40262-023-01329-0","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T15:03:06Z","timestamp":1703170986000},"page":"183-196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Toward Model-Based Informed Precision Dosing of Vancomycin in Hematologic Cancer Patients: A First Step"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8454-9807","authenticated-orcid":false,"given":"Jessica","family":"Le Blanc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Projean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Savignac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"L\u00e9veill\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Pier","family":"Ducas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Brisebois-Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Marsot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"issue":"4","key":"1329_CR1","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56-93.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1329_CR2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.hoc.2010.11.008","volume":"25","author":"JR Wingard","year":"2011","unstructured":"Wingard JR, Hsu J, Hiemenz JW. Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. Hematol Oncol Clin North Am. 2011;25(1):101\u201316.","journal-title":"Hematol Oncol Clin North Am"},{"key":"1329_CR3","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer-Related Infections. National Comprehensive Cancer Network. 2022; version 3."},{"issue":"1","key":"1329_CR4","first-page":"21","volume":"31","author":"JH Martin","year":"2010","unstructured":"Martin JH, Norris R, Barras M, Roberts J, Morris R, Doogue M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society Of Infectious Diseases Pharmacists. Clin Biochem Rev. 2010;31(1):21\u20134.","journal-title":"Clin Biochem Rev"},{"issue":"11","key":"1329_CR5","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"MJ Rybak","year":"2020","unstructured":"Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77(11):835\u201364.","journal-title":"Am J Health Syst Pharm"},{"issue":"2","key":"1329_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab651","volume":"9","author":"TP Lodise","year":"2022","unstructured":"Lodise TP, Scheetz M, Carreno JJ, Chambers H, Fowler V, Holland TL. Associations between vancomycin exposure and acute kidney injury within the recommended area under the curve therapeutic exposure range among patients with methicillin-resistant staphylococcus aureus bloodstream infections. Open Forum Infect Dis. 2022;9(2): ofab651.","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"1329_CR7","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1093\/cid\/ciaa1744","volume":"72","author":"TP Lodise","year":"2021","unstructured":"Lodise TP, Drusano G. Vancomycin area under the curve-guided dosing and monitoring for adult and pediatric patients with suspected or documented serious methicillin-resistant staphylococcus aureus infections: putting the safety of our patients first. Clin Infect Dis. 2021;72(9):1497\u2013501.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1329_CR8","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/cpt.2202","volume":"109","author":"SG Wicha","year":"2021","unstructured":"Wicha SG, M\u00e4rtson A-G, Nielsen EI, Koch BCP, Friberg LE, Alffenaar J-W, et al. From therapeutic drug monitoring to model-informed precision dosing for antibiotics. Clin Pharmacol Ther. 2021;109(4):928\u201341.","journal-title":"Clin Pharmacol Ther"},{"key":"1329_CR9","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.2147\/IDR.S239095","volume":"13","author":"N He","year":"2020","unstructured":"He N, Dong F, Liu W, Zhai S. A systematic review of vancomycin dosing in patients with hematologic malignancies or neutropenia. Infect Drug Resist. 2020;13:1807\u201321.","journal-title":"Infect Drug Resist."},{"issue":"4","key":"1329_CR10","first-page":"1","volume":"7","author":"MT Ghehi","year":"2013","unstructured":"Ghehi MT, Rezaee S, Hayatshahi A, Hadjibabaie M, Gholami K, Javadi M, et al. Vancomycin pharmacokinetic parameters in patients undergoing hematopoietic stem cell transplantation (HSCT). Int J Hematol Oncol Stem Cell Res. 2013;7(4):1\u20139.","journal-title":"Int J Hematol Oncol Stem Cell Res."},{"issue":"1","key":"1329_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1177\/1078155220985317","volume":"28","author":"S Arjangpour","year":"2022","unstructured":"Arjangpour S, Sadeghi K, Solduzian M, Mousavi SA. Vancomycin pharmacokinetic parameters in patients undergoing hematopoietic stem cell transplantation. J Oncol Pharm Pract. 2022;28(1):101\u20138.","journal-title":"J Oncol Pharm Pract"},{"issue":"6","key":"1329_CR12","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1128\/AAC.32.6.848","volume":"32","author":"KA Rodvold","year":"1988","unstructured":"Rodvold KA, Blum RA, Fischer JH, Zokufa HZ, Rotschafer JC, Crossley KB, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother. 1988;32(6):848\u201352.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"1329_CR13","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1177\/1078155219851834","volume":"26","author":"T Nakashima","year":"2020","unstructured":"Nakashima T, Ohno T, Koido K, Hashimoto H, Terakado H. Accuracy of predicting the vancomycin concentration in Japanese cancer patients by the Sawchuk-Zaske method or Bayesian method. J Oncol Pharm Pract. 2020;26(3):543\u20138.","journal-title":"J Oncol Pharm Pract"},{"issue":"12","key":"1329_CR14","doi-asserted-by":"publisher","first-page":"4934","DOI":"10.1128\/AAC.49.12.4934-4941.2005","volume":"49","author":"D Buelga","year":"2005","unstructured":"Buelga D, Del Mar Fernandez De Gatta M, Herrera EV, Dominguez-Gil A, Garcia MJ. Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies. Antimicrob Agents Chemother. 2005;49(12):4934\u201341.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"1329_CR15","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2165\/00003088-200948040-00005","volume":"48","author":"M Fern\u00e1ndez de Gatta Mdel","year":"2009","unstructured":"Fern\u00e1ndez de Gatta Mdel M, Santos Buelga D, S\u00e1nchez Navarro A, Dominguez-Gil A, Garc\u00eda MJ. Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokinetic\/pharmacodynamic analysis. Clin Pharmacokinet. 2009;48(4):273\u201380.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"1329_CR16","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00228-019-02657-6","volume":"75","author":"D Bury","year":"2019","unstructured":"Bury D, Ter Heine R, van de Garde EMW, Nijziel MR, Grouls RJ, Deenen MJ. The effect of neutropenia on the clinical pharmacokinetics of vancomycin in adults. Eur J Clin Pharmacol. 2019;75(7):921\u20138.","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"1329_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112008","volume":"9","author":"MB Haeseker","year":"2014","unstructured":"Haeseker MB, Croes S, Neef C, Bruggeman CA, Stolk LM, Verbon A. Vancomycin dosing in neutropenic patients. PLoS ONE. 2014;9(11): e112008.","journal-title":"PLoS ONE"},{"key":"1329_CR18","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.cca.2016.12.021","volume":"465","author":"MH Choi","year":"2017","unstructured":"Choi MH, Choe YH, Lee SG, Jeong SH, Kim JH. Neutropenia is independently associated with sub-therapeutic serum concentration of vancomycin. Clin Chim Acta. 2017;465:106\u201311.","journal-title":"Clin Chim Acta"},{"issue":"3","key":"1329_CR19","doi-asserted-by":"publisher","first-page":"295","DOI":"10.23876\/j.krcp.19.042","volume":"38","author":"MH Rosner","year":"2019","unstructured":"Rosner MH, Perazella MA. Acute kidney injury in the patient with cancer. Kidney Res Clin Pract. 2019;38(3):295\u2013308.","journal-title":"Kidney Res Clin Pract."},{"issue":"5","key":"1329_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2022.106579","volume":"59","author":"A Heus","year":"2022","unstructured":"Heus A, Uster DW, Grootaert V, Vermeulen N, Somers A, In\u2019t Veld DH, et al. Model-informed precision dosing of vancomycin via continuous infusion: a clinical fit-for-purpose evaluation of published PK models. Int J Antimicrob Agents. 2022;59(5): 106579.","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"1329_CR21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.jiac.2023.01.010","volume":"29","author":"T Belabbas","year":"2023","unstructured":"Belabbas T, Yamada T, Egashira N, Hirota T, Suetsugu K, Mori Y, et al. Population pharmacokinetic model and dosing optimization of vancomycin in hematologic malignancies with neutropenia and augmented renal clearance. J Infect Chemother. 2023;29(4):391\u2013400.","journal-title":"J Infect Chemother"},{"issue":"9","key":"1329_CR22","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1002\/jcph.1106","volume":"58","author":"A Okada","year":"2018","unstructured":"Okada A, Kariya M, Irie K, Okada Y, Hiramoto N, Hashimoto H, et al. Population pharmacokinetics of vancomycin in patients undergoing allogeneic hematopoietic stem-cell transplantation. J Clin Pharmacol. 2018;58(9):1140\u20139.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"1329_CR23","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","volume":"120","author":"A Khwaja","year":"2012","unstructured":"Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179\u201384.","journal-title":"Nephron Clin Pract"},{"issue":"9","key":"1329_CR24","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1329_CR25","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2146\/ajhp080434","volume":"66","author":"M Rybak","year":"2009","unstructured":"Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66(1):82\u201398.","journal-title":"Am J Health Syst Pharm"},{"key":"1329_CR26","unstructured":"Mandell B, Bennett JE, Dolin R. Principles and Practice of Infectious Diseases. 6th ed; 2005."},{"issue":"11","key":"1329_CR27","first-page":"650","volume":"8","author":"MM McCarron","year":"1974","unstructured":"McCarron MM, Devine BJ. Clinical pharmacy: case studies: case number 25 gentamicin therapy. Drug Intell Clin Pharm. 1974;8(11):650\u20135.","journal-title":"Drug Intell Clin Pharm"},{"key":"1329_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-023-09962-w","author":"U Nyman","year":"2023","unstructured":"Nyman U, Leander P, Liss P, Sterner G, Brismar T. Absolute and relative GFR and contrast medium dose\/GFR ratio: cornerstones when predicting the risk of acute kidney injury. Eur Radiol. 2023. https:\/\/doi.org\/10.1007\/s00330-023-09962-w. (Epub 4 Aug 2023).","journal-title":"Eur Radiol"},{"issue":"2","key":"1329_CR29","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.cmpb.2007.12.002","volume":"90","author":"E Comets","year":"2008","unstructured":"Comets E, Brendel K, Mentr\u00e9 F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed. 2008;90(2):154\u201366.","journal-title":"Comput Methods Programs Biomed"},{"issue":"1","key":"1329_CR30","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/FTD.0000000000000250","volume":"38","author":"M Haeseker","year":"2016","unstructured":"Haeseker M, Croes S, Neef C, Bruggeman C, Stolk L, Verbon A. Evaluation of vancomycin prediction methods based on estimated creatinine clearance or trough levels. Ther Drug Monit. 2016;38(1):120\u20136.","journal-title":"Ther Drug Monit"},{"issue":"4","key":"1329_CR31","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1128\/AAC.21.4.575","volume":"21","author":"RA Blouin","year":"1982","unstructured":"Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO Jr. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother. 1982;21(4):575\u201380.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"1329_CR32","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1086\/491712","volume":"42","author":"MJ Rybak","year":"2006","unstructured":"Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006;42(Suppl 1):S35\u20139.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1329_CR33","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3390\/jcm11030623","volume":"11","author":"G Milone","year":"2022","unstructured":"Milone G, Bellofiore C, Leotta S, Milone GA, Cupri A, Duminuco A, et al. Endothelial dysfunction after hematopoietic stem cell transplantation: a review based on physiopathology. J Clin Med. 2022;11(3):623.","journal-title":"J Clin Med"},{"issue":"12","key":"1329_CR34","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1016\/j.bbmt.2017.08.021","volume":"23","author":"G Rond\u00f3n","year":"2017","unstructured":"Rond\u00f3n G, Saliba RM, Chen J, Ledesma C, Alousi AM, Oran B, et al. Impact of fluid overload as new toxicity category on hematopoietic stem cell transplantation outcomes. Biol Blood Marrow Transplant. 2017;23(12):2166\u201371.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"1329_CR35","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s40262-020-00866-2","volume":"59","author":"A Aljutayli","year":"2020","unstructured":"Aljutayli A, Marsot A, Nekka F. An update on population pharmacokinetic analyses of vancomycin, Part I. In adults. Clin Pharmacokinet. 2020;59(6):671\u201398.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1329_CR36","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/j.1365-2710.2008.01016.x","volume":"34","author":"M Yamamoto","year":"2009","unstructured":"Yamamoto M, Kuzuya T, Baba H, Yamada K, Nabeshima T. Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type. J Clin Pharm Ther. 2009;34(4):473\u201383.","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"1329_CR37","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/phar.2231","volume":"39","author":"AM Cook","year":"2019","unstructured":"Cook AM, Hatton-Kolpek J. Augmented renal clearance. Pharmacotherapy. 2019;39(3):346\u201354.","journal-title":"Pharmacotherapy"},{"key":"1329_CR38","volume-title":"Goldman-Cecil Medicine","author":"DWBH Landry","year":"2020","unstructured":"Landry DWBH. Approach to the patient with renal disease. In: Godlman L, Schafer AI, editors. Goldman-Cecil Medicine. 26th ed. Philadelphia: Elsevier; 2020.","edition":"26"},{"key":"1329_CR39","unstructured":"Hosten AO. BUN and Creatinine. In: Walker HK, Hall WD, Hurst JW (eds). Clinical Methods: The History, Physical, and Laboratory Examinations. Boston: Butterworths Copyright \u00a9 1990, Butterworth Publishers, a division of Reed Publishing; 1990."},{"issue":"4","key":"1329_CR40","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1128\/AAC.25.4.433","volume":"25","author":"GR Matzke","year":"1984","unstructured":"Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother. 1984;25(4):433\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"1329_CR41","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1007\/s00228-019-02756-4","volume":"75","author":"N Okada","year":"2019","unstructured":"Okada N, Chuma M, Azuma M, Nakamura S, Miki H, Hamano H, et al. Effect of serum concentration and concomitant drugs on vancomycin-induced acute kidney injury in haematologic patients: a single-centre retrospective study. Eur J Clin Pharmacol. 2019;75(12):1695\u2013704.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1329_CR42","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1128\/AAC.01653-13","volume":"58","author":"MN Neely","year":"2014","unstructured":"Neely MN, Youn G, Jones B, Jelliffe RW, Drusano GL, Rodvold KA, et al. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob Agents Chemother. 2014;58(1):309\u201316.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1329_CR43","first-page":"3","volume":"6","author":"JJ Stewart","year":"2021","unstructured":"Stewart JJ, Jorgensen SC, Dresser L, Lau TT, Gin A, Thirion DJ, et al. A Canadian perspective on the revised 2020 ASHP-IDSA-PIDS-SIDP guidelines for vancomycin AUC-based therapeutic drug monitoring for serious MRSA infections. J Assoc Med Microbiol Infect Dis Can. 2021;6(1):3\u20139.","journal-title":"J Assoc Med Microbiol Infect Dis Can."},{"issue":"6","key":"1329_CR44","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1128\/AAC.02564-13","volume":"58","author":"W Zhao","year":"2014","unstructured":"Zhao W, Zhang D, Fakhoury M, Fahd M, Duquesne F, Storme T, et al. Population pharmacokinetics and dosing optimization of vancomycin in children with malignant hematological disease. Antimicrob Agents Chemother. 2014;58(6):3191\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1329_CR45","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1177\/1078155211402107","volume":"18","author":"IA Jarkowski","year":"2012","unstructured":"Jarkowski IA, Forrest A, Sweeney RP, Tan W, Segal BH, Almyroudis N, et al. Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population. J Oncol Pharm Pract. 2012;18(1):91\u20136.","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"1329_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/11596390-000000000-00000","volume":"51","author":"A Marsot","year":"2012","unstructured":"Marsot A, Boulamery A, Bruguerolle B, Simon N. Vancomycin: a review of population pharmacokinetic analyses. Clin Pharmacokinet. 2012;51(1):1\u201313.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1329_CR47","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1208\/s12248-012-9407-9","volume":"14","author":"XS Xu","year":"2012","unstructured":"Xu XS, Yuan M, Karlsson MO, Dunne A, Nandy P, Vermeulen A. Shrinkage in nonlinear mixed-effects population models: quantification, influencing factors, and impact. AAPS J. 2012;14(4):927\u201336.","journal-title":"AAPS J"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01329-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-023-01329-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01329-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T15:03:21Z","timestamp":1707491001000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-023-01329-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,21]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1329"],"URL":"https:\/\/doi.org\/10.1007\/s40262-023-01329-0","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,21]]},"assertion":[{"value":"18 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Am\u00e9lie Marsot received financial support from the Fonds de Recherche du Qu\u00e9bec-Sant\u00e9 (FRQS) Research Scholars-Junior 1 (Young Researcher Establishment) Career Scholarship.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jessica Le Blanc, Denis Projean, Sandra Savignac, Sophie L\u00e9veill\u00e9, Marie-Pier Ducas, Annie Brisebois-Boyer, and Am\u00e9lie Marsot declare they have no competing interests associated with this publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This clinical trial was approved by the local human research and ethics committee (REB) [CIUSSS de l\u2019Est-de-l\u2019\u00cele-de-Montr\u00e9al - 2021-2482] and was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All participants in the prospective cohort provided written consent to participate. Authorization from the local REB was obtained to collect data retrospectively from chart review.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate and for Publication"}},{"value":"Individual patient data from Maisonneuve-Rosemont Hospital is not publicly accessible.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"The code is available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conception and design: All authors. PK model development and related computational analysis: AM. Statistical analysis: JLB, DP, AM. Data interpretation: All authors. Writing \u2013 original draft preparation: DP, JLB, AM, AB. Writing \u2013 review and editing: All authors.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}